GlucoTrack Shares Surged on AI Partnership Deal
The New Jersey biotech firm signed its first external fee-for-service agreement to identify brain tumor therapeutics.
Live Poll
Do you generally trust the long-term potential of small-cap biotech stocks after market-moving news?